Cryo cell International Inc (CCEL) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CCEL Annual Cash Flow →
The data below summarizes Cryo cell International Inc's cash flow activity from Feb 28 2025 to Feb 28 2026, enabling a period-by-period view of cash movement.
Quarterly Report, GAAP in USD millions
ITEM
(Feb 28 2026)
3 Months
(Nov 30 2025) (Aug 31 2025) (May 31 2025) (Feb 28 2025)
Operating Activities
Income0.05
Depreciation & amortization0.24
Amortization of Other Assets0.01
Increase (Decrease) in Deferred Revenue0.00
Other Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.21
Increase (Decrease) in Inventories0.05
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.16
Income (Loss) from Equity Method Investments0.00
Gain (Loss) on Contract Termination0.00
Depreciation And Amortization Expense-
Abandonment Of Patents-
Equity In Income Loss Of Affiliates-
Write Off Of Note Receivable-
Increase Decrease In Deposits And Other Assets-0.11
Goodwill And Intangible Asset Impairment-
Marketable Securities Unrealized Gain Loss0.24
Increase Decrease In Operating Lease Liability-0.11
Operating Lease Right Of Use Asset Amortization Expense0.10
Increase Decrease In Contract With Customer Liability0.76
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-0.18
Increase (Decrease) in Accounts Payable0.43
Increase (Decrease) in Accrued Liabilities-1.39
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.18
Other Working Capital0.02
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities0.65
Investing Activities
Capital Expenditures-0.07
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.59
Short-term Investments Acq.0.00
Real Estate Investments0.00
Purchases Of Marketable Securities And Other Investments-
Payment Of Duke License Agreement-
Payments To Acquire Marketable Securities And Other Investments-0.51
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Gross0.00
Payments to Fund Long-term Loans to Related Parties0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.02
Financing Activities
Short-term debt Net-0.70
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.04
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Increase Decrease In Long Term Liability Revenue Sharing Agreements-
Extinguishment Of Revenue Sharing Agreements-
Litigation Settlement Amount Awarded To Other Party-
Payment Of Earnout-
Payments For Extinguishment Of Revenue Sharing Agreements-
Issuance Costs Associated With The Proceeds From The Note Payable-
Proceeds From Swap Termination-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.74
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow0.58
Total Cash Flow-0.07
4 historic quarters locked

Sign in to unlock the full Cryo cell International Inc cash flow history.

About Cryo Cell International Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-304834

Figures are derived from filed reports and may be restated. Historical data is subject to revision.